A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA)

Since only 3 subjects were enrolled in this study, the efficacy data is not interpretable and
will not be presented. Only Adverse Event (AE) data will be summarized in a table, with
frequency counts and percentages.

Inclusion Criteria:

- Diagnosed with adult-onset Rheumatoid Arthritis (RA) >6 months and <3 years

- Active RA

- Must have failed at least one disease modifying Anti Rheumatic Drug (DMARD) treatment

- Subject can have attempted no more than one previous Anti Tumor Necrosis factor
(anti-TNF) and discontinued due to drug intolerance

Exclusion Criteria:

- Subject cannot have a second non-inflammatory musculoskeletal condition

- Subject cannot have a diagnosis of any other inflammatory arthritis

- Subject cannot have any previously infected prosthesis

- Subject cannot have arthroplasties in any of the joints assessed in the study

- Subject cannot have a history of chronic infections

- Subject cannot have known Tuberculosis (TB) disease, high risk of acquiring TB, or
latent TB infection

- Subject cannot have a history of or current Lymphoproliferative disorder

- Subject cannot have known Human Immunodeficiency Virus (HIV) infection

- Subject cannot have received a live or attenuated vaccine within 8 weeks

- Subject cannot have current or history of malignancy

- Subject cannot have a history of blood disorders

- Subject cannot have a current or recent history of severe, progressive, and/or
uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary,
cardiac, neurological or cerebral disease

- Subjects must not have a history of adverse reaction to Polyethylene glycol (PEG), a
protein medicinal product, or ultrasound gel applied to the skin